Equity Investment (Details Narrative) - USD ($) |
12 Months Ended | ||
|---|---|---|---|
Mar. 12, 2021 |
Dec. 31, 2021 |
Dec. 31, 2020 |
|
| Defined Benefit Plan Disclosure [Line Items] | |||
| Aggregrate investment | $ 6,000,000 | ||
| Equity investment | 5,000,000 | ||
| Convertable note investment | 1,000,000 | ||
| Iliad [Member] | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Aggregrate investment | 6,000,000 | ||
| Equity investment | 5,000,000 | ||
| Equity investment net loss | $ 999,000 | $ 787,000 | |
| Iliad [Member] | Class C Units [Member] | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Ownership percentage not fully diluted | 9.50% | ||
| Ownership percentage fully diluted | 7.20% | ||
| I Liad Biotechnologies L L C [Member] | |||
| Defined Benefit Plan Disclosure [Line Items] | |||
| Additional convertable note investment | $ 1,000,000 | ||
| Maximum convertible debt offering | $ 23,500,000 | ||
| Interest rate | 6.00% | ||
| Notes conversion, description | The Notes are required to be converted into a Qualified Financing (minimum financing of $15 million) at the lesser of (i) 80% of the price paid per unit in such offering or (ii) a price based on an enterprise value of $176,000,000. In addition, the Notes shall convert in the event of a merger at the lower of an enterprise value of $176,000,000 or the stated valuation of ILiAD in the merger transaction. In the event of a change-in-control, noteholders will also have the option to have the Notes repaid except in a Qualified Financing or a stock-for-stock merger. | ||